Related Experiment Video
Updated: Aug 7, 2026
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Time to Positivity of a Rapid HBsAg Assay as a Surrogate Marker of Quantitative HBsAg: Multicentre Proof-of-Concept
Asegedech Asmamaw1,2, Judit Romero3,4, Nega Berhe2,5
1Department of Medical Laboratory Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background And Aims:
Point-of-care (POC) diagnostics for hepatitis B virus (HBV) are limited to qualitative results. This study evaluated whether the time to positivity of a rapid HBsAg assay could serve as a surrogate marker of quantitative HBsAg (qHBsAg) and virological activity.
Methods:
This multicentre, prospective proof-of-concept study included cohorts from Spain and Ethiopia. Adults with chronic or resolved HBV infection and healthy controls were enrolled. Paired venous and capillary blood samples were collected; capillary blood was tested with Determine HBsAg2 rapid test recording time to positivity, while qHBsAg and HBV DNA were measured using immunoassay and PCR, respectively.
Results:
A total of 513 HBsAg-positive individuals were included (263 Spain; 250 Ethiopia). All healthy controls and individuals with resolved infection tested negative. Time to positivity showed an inverse correlation with qHBsAg in both cohorts (Spain: r = -0.749; Ethiopia: r = -0.374; p < 0.001 for both). No association was observed between time to positivity and HBV DNA levels. The performance to identify patients with HBsAg levels < 1000 IU/mL was higher in Spain (AUROC 0.86) than in Ethiopia (AUROC 0.65). Better performance was observed for detecting HBsAg levels < 100 IU/mL in both countries (AUROC 0.96 and 0.77, respectively).
Conclusions:
Time to positivity in a rapid HBsAg assay correlated inversely with qHBsAg and may provide a simple, semi-quantitative estimate of antigen burden. Although unrelated to HBV DNA, it could expand the utility of point-of-care HBsAg testing beyond qualitative diagnosis, particularly where quantitative HBsAg assays are unavailable.
